The Value of Target Therapy in Metastatic Cancer Colon | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 20, Volume 74, Issue 7, January 2019, Pages 1607-1615 PDF (422.49 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2019.28267 | ||
| Authors | ||
| Ahmed Yousery Al Agamawy1; Sohier Sayed Ismail2; Shaymaa Mamdouh Anwar Ibrahim* 1 | ||
| 1Clinical Oncology & Nuclear Medicine Department, Al-Azhar University | ||
| 2Clinical Oncology & Nuclear Medicine Department, Ain Shams University, Cairo, Egypt | ||
| Abstract | ||
| Background: Colorectal cancer is the third leading cause of cancer-related deaths in the United States when men and women are considered separately, and the second leading cause when both sexes are combined It is expected to cause about 49,700 deaths during 2015. Aim of the Work: The present work was aimed to study the efficacy of treatment of metastatic cancer colon (KRAS wild type) with chemotherapy plus anti-EGFR (Erbitux) and chemotherapy alone. Patients and Methods: This phase II prospective study included a total of 37 patients of metastatic cancer colon (KRAS wild type) treated with chemotherapy plus anti-EGFR (Erbitux) and chemotherapy alone for (KRAS wild type) attending at Police Hospital. This study was conducted between September 2016 and August 2018. Results: We have studied the value of adding target therapy in the metastatic colon cancer patients. Some of them received chemotherapy with cetuximab as target therapy versus patients received chemotherapy alone. In the current study, median progression-free survival (PFS) of the whole studied sample (n =37) was 10.0 months (range.3.0.-.21.0). Median survival was significantly higher in the chemotherapy and cetuxumab group (P: less than 0.001). Using cox regression analysis group with cetuximab associated with better survival (P=0.047) with protective hazard ratio of 0.974. The cumulative PFS proportion is presented at 12 months. Median overall survival of whole studied samples (n=37) was 21.0 months (range 18-23 months) and there were 25 cases dead and all cases progressed. Median OS was higher in chemotherapy with cetuximab group and was of a significant difference (P=0.001). There were others factors studied their relation to OS like age but no significant difference bit older patient had better OS by (34.8 % vs 28.6 %), also PS no significant difference but patient with PS =0 had better OS by (41.7% vs 28%) according to RT and LT colon there was LCC with better OS than RCC but no significant difference but LT site of colon had better survival by (42.9 %vs 18.8%). Conclusion: Cetuximab was beneficial in down-staging programs and significantly improve progression-free survival and response rates and overall survival for patients with metastatic colorectal cancer | ||
| Keywords | ||
| Target Therapy; Metastatic Cancer Colon | ||
|
Statistics Article View: 158 PDF Download: 440 |
||
